公开(公告)号：EP1740531A1

公开(公告)日：2007-01-10

申请号：EP05733398.1

申请日：2005-04-13

申请人： KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  Jeil Pharmaceutical Co., Ltd. ,  Korea Research Institute of Bioscience and Biotechnology ,  CJ Corp

发明人： CHEON, Hyae Gyeong ,  YOO, Sung-Eun ,  KIM, Sung Soo ,  YANG, Sung-Don ,  KIM, Kwang-Rok ,  RHEE, Sang Dal ,  AHN, Jin Hee ,  KANG, Seung Kyu ,  JUNG, Won Hoon ,  PARK, Sung Dae ,  KIM, Nam Gee ,  LEE, Jang Hyuk ,  HUH, Sun Chul ,  LEE, Jae Mok ,  SONG, Seog Beom ,  KWON, Soon Ji ,  KIM, Jong H. ,  LEE, Jeong-Hyung ,  KIM, Seung Jun

IPC分类号： C07C251/44

CPC分类号： C07D213/30 ,  C07C291/02 ,  C07C309/66 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2603/74 ,  C07D213/53 ,  C07D233/64 ,  C07D277/24 ,  C07D295/088 ,  C07D295/185 ,  C07D307/54 ,  C07D317/60 ,  C07D317/70 ,  C07D333/24 ,  C07D333/28 ,  C07D417/12

摘要： The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

摘要翻译： 式（I）的本发明的茚衍生物能够选择性地调节过氧化物酶体增殖物激活受体（PPAR）的活性，引起无副作用，因此它们可用于治疗和预防由PPAR调节的病症， 代谢综合征如糖尿病，肥胖症，动脉硬化，高脂血症，高胰岛素血症和高血压，炎性疾病如骨质疏松症，肝硬化和哮喘以及癌症。

公开(公告)号：EP1692169A1

公开(公告)日：2006-08-23

申请号：EP04799975.0

申请日：2004-11-01

申请人： Korea Institute of Science and Technology ,  Jeil Pharmaceutical Co., Ltd.

发明人： YANG, Beom-Seok ,  PARK, Sung-Dae

IPC分类号： C07K14/705

CPC分类号： C07K14/705 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/35 ,  C12N9/1205

摘要： The present invention relates to a protein containing a modified DDR (Discoidin Domain Receptor) 2 cytosolic tyrosine kinase domain having an increased autophosphorylation and tyrosine kinase activity; a method for preparing a large amount of a protein containing DDR2 cytosolic tyrosine kinase domain, having an increased autophosphorylation and tyrosine kinase activity by inducing phosphorylations of tyrosines by a co-expression with Src or Src related proteins in host cells, or by H2O2 processing of host cells, or a site directed mutation modifying at least one of tyrosines to other amino acid; and a use thereof as a target material in developing medical drugs for treating a disease caused by an excessively activated DDR2 autophosphorylation and tyrosine kinase activity.